Palisade Bio (PALI) Amortizatization of Intangibles (2020 - 2021)
Palisade Bio (PALI) posted quarterly Amortizatization of Intangibles of $5000.0 for Q4 2021, down 97.06% year-over-year from $170000.0 in Q4 2020, and down 96.18% quarter-over-quarter from $131000.0 in Q3 2021.
Powered by 
Analysis
Palisade Bio (PALI) Amortizatization of Intangibles (2020 - 2021) Analysis & Trends
Palisade Bio (PALI) has reported Amortizatization of Intangibles for 2 consecutive years, with $5000.0 the latest figure, recorded in Q4 2021.
- In Q4 2021, Amortizatization of Intangibles fell 97.06% year-over-year to $5000.0; the TTM figure through Sep 2022 stood at $5000.0 (down 99.8% YoY), while the FY2021 annual figure was $2.3 million, up 1057.92% from the prior year.
- Amortizatization of Intangibles eased to $5000.0 in Q4 2021 per PALI's latest filing, from $131000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.6 million in Q1 2021 and bottomed at $5000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 5,000.00 |
| Sep 30, 2021 | 131,000.00 |
| Jun 30, 2021 | 613,000.00 |
| Mar 31, 2021 | 1.59 Mn |
| Dec 31, 2020 | 170,000.00 |
| Sep 30, 2020 | 20,000.00 |